This might depend at least in part upon the fine modulation of the cytoprotective and antioxidant KEAP1/NRF2 pathway resulting in sex differences in the occurrence and severity of MASLD. This evidence concerns the gene KEAP1 and metabolic dysfunction-associated steatotic liver disease.